Mai	neCare COVID-19 Vaccine Code Coverage		Updated A	April 18, 2023
Code	Description	Code Effective Dates	Rate Effective 01/01/2022	Rate Effective 01/01/2023
Pfizer (COVID-19 Vaccine Administration for Ages 6 months to 4 years			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for	6/17/2022-		
91308	intramuscular use	04/18/23	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2	6/17/2022-		
0081A	mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2	6/17/2022-		
0082A	mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, preservative free, 3 mcg/0.2	6/17/2022-		
0083A	mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	12/08/2022	\$36.98*	N/A
Pfizer (COVID-19 Bivalent Vaccine Administration for Ages 6 months to 4 years	1	T	
	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for			
91317	intramuscular use	12/08/22	\$0**	\$0**

	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3			
0173A	mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	12/08/22	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3			
0174A	mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	03/14/2023	N/A	TBD
Pfizer C	OVID-19 Vaccine and Booster Administration for Ages 5 to 11			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10			
	mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for	10/29/2021-		
91307	intramuscular use	04/18/23	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2	10/29/2021-		
0071A	mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2	10/29/2021-		
0072A	mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2	1/3/2022-		
0073A	mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (Sars-Cov-2) (coronavirus disease [COVID-			
	19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL	5/17/2022-		
0074A	dosage, diluent reconstituted, tris-sucrose formulation; booster dose	10/12/22	\$36.98*	N/A
Pfizer C	OVID-19 Bivalent Vaccine Administration for Ages 5 to 11			

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose Prizer COVID-19 Vaccine, daministration for Ages 12 and Up Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 8/12/2021- 04/18/23 \$36.98* \$39.11* Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protei					
free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 0154A mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose Pfizer COVID-19 Vaccine Administration for Ages 12 and Up Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 O002A [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 30 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 8/12/2021- 04/18/23 \$36.98* \$39.11* Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 8/12/2021- 04/18/23 \$36.98* \$39.11*					
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCOV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 neg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose prize acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 neg/0.3mL dosage, diluent reconstituted, for intramuscular use negrous neg/0.3mL dosage, diluent reconstituted; first dose neg/0.3mL dosage, diluent reconstituted; for one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 neg/0.3mL dosage, diluent reconstituted; second dose neg/0.3mL dosage, diluent reconstituted; second dose neg/0.3mL dosage, diluent reconstituted; third dose neg/0.3mL dosage, diluent reconstituted; booster dose neg/0.3mL dosage, diluent reconstituted; booster dose neg/0.3mL dosage, di					
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCOV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 10/12/22 \$36.98* \$39.11*					
respiratory syndrome coronavirus 2 (SARSCOV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 0154A mcg/0.2 mL dosage, diluent reconstituted; tris-sucrose formulation, booster dose Pfizer COVID-19 Vaccine Administration for Ages 12 and Up Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 91300 mcg/0.3mL dosage, diluent reconstituted; for intramuscular use Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 0001A mcg/0.3mL dosage, diluent reconstituted; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 0002A mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 0002A mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 Immunization administration by intramuscular injection of severe acute respi	91315		10/12/22	\$0**	\$0**
COVID-19) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 10/12/22 \$36.98* \$39.11*					
Distance					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose 12/11/2020-0001A mcg/0.3mL dosage, diluent reconstituted; first dose 04/18/23 \$36.98* \$39.11*					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-governed free, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021	0154A	mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	10/12/22	\$36.98*	\$39.11*
disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 ML dosage, diluent reconstituted: booster dose Valid	Pfizer C	COVID-19 Vaccine Administration for Ages 12 and Up			
91300 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use 04/18/23 \$0** \$0**		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus			
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30		disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30	12/11/2020-		
respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose N/A	91300	mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	04/18/23	\$0**	\$0**
[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30		Immunization administration by intramuscular injection of severe acute			
0001A mcg/0.3mL dosage, diluent reconstituted; first dose 04/18/23 \$36.98* \$39.11*		respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose 04/18/23 \$36.98* \$39.11* Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose 04/18/23 \$36.98* \$39.11* Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021- good-4 mL dosage, diluent reconstituted: booster dose 8/31/2022 \$36.98* N/A		[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30	12/11/2020-		
respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose N/A	0001A	mcg/0.3mL dosage, diluent reconstituted; first dose	04/18/23	\$36.98*	\$39.11*
[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose N/A		Immunization administration by intramuscular injection of severe acute			
0002Amcg/0.3mL dosage, diluent reconstituted; second dose04/18/23\$36.98*\$39.11*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.38/12/2021-0003A8/12/2021-004/18/23Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.39/22/2021-0004AImage: MRNA-LNP of the protein of the		respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 8/12/2021-0003A mL dosage, diluent reconstituted; third dose 04/18/23 \$36.98* \$39.11* Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021-0004A mL dosage, diluent reconstituted: booster dose 8/31/2022 \$36.98* N/A		[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30	12/11/2020-		
respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose S36.98* S36.98*	0002A	mcg/0.3mL dosage, diluent reconstituted; second dose	04/18/23	\$36.98*	\$39.11*
[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose 04/18/23 \$36.98* \$39.11* Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021- mL dosage, diluent reconstituted: booster dose 8/31/2022 \$36.98* N/A		Immunization administration by intramuscular injection of severe acute			
0003AmL dosage, diluent reconstituted; third dose04/18/23\$36.98*\$39.11*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.39/22/2021- 8/31/20229/22/2021- \$36.98*		respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021- mL dosage, diluent reconstituted: booster dose 8/31/2022 \$36.98* N/A		[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3	8/12/2021-		
respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose 9/22/2021- 8/31/2022 \$36.98* N/A	0003A	mL dosage, diluent reconstituted; third dose	04/18/23	\$36.98*	\$39.11*
[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 9/22/2021- 0004A mL dosage, diluent reconstituted: booster dose 8/31/2022 \$36.98* N/A		Immunization administration by intramuscular injection of severe acute			
0004A mL dosage, diluent reconstituted: booster dose 8/31/2022 \$36.98* N/A		respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
		[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3	9/22/2021-		
Pfizer Ready-to Use COVID-19 Vaccine Administration for Ages 12 and Up	0004A	mL dosage, diluent reconstituted: booster dose	8/31/2022	\$36.98*	N/A
	Pfizer R	Ready-to Use COVID-19 Vaccine Administration for Ages 12 and Up			

	La compagnition of			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus	1 /2 /2 02 2		
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30	1/3/2022-		
91305	mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use	04/18/23	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3	1/3/2022-		
0051A	mL dosage, tris-sucrose formulation; first dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3	1/3/2022-		
0052A	mL dosage, tris-sucrose formulation; second dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3	1/3/2022-		
0053A	mL dosage, tris-sucrose formulation; third dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3	1/3/2022-		
0054A	mL dosage, tris-sucrose formulation; booster dose	8/31/2022	\$36.98*	N/A
Pfizer C	OVID-19 Bivalent Vaccine Booster Administration for Ages 12 and Up			
	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative			
91312	free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	8/31/2022	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 30			
0124A	mcg/0.3 mL dosage, tris-sucrose formulation, booster dose	8/31/2022	\$36.98*	\$39.11*
Modern	a COVID-19 Vaccine Ages 6 months to 5 years			

	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25	6/17/2022-		
91311	mcg/0.25 mL dosage, for intramuscular use	04/18/23	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25	6/17/2022-		
0111A	mcg/0.25 mL dosage; first dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25	6/17/2022-		
0112A	mcg/0.25 mL dosage; second dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25	6/17/2022-		
0113A	mcg/0.25 mL dosage; third dose	04/18/23	\$36.98*	\$39.11*
Modern	a COVID-19 Bivalent Vaccine Booster Ages 6 months to 5 years			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative			
91316	free, 10 mcg/0.2 mL dosage, for intramuscular use	12/08/22	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative			
0164A	free, 10 mcg/0.2 mL dosage, booster dose	12/08/22	\$36.98*	\$39.11*
Modern	a COVID-19 Vaccine Ages 6 to 11			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50	3/29/2022-		
91309	mcg/0.5 mL dosage, for intramuscular use	04/18/23	\$0**	\$0**

	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5	6/17/2022-		
0091A	mL dosage; first dose, when administered to individuals 6 through 11 years	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5	6/17/2022-		
0092A	mL dosage; second dose, when administered to individuals 6 through 11 years	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5	6/17/2022-		
0093A	mL dosage; third dose, when administered to individuals 6 through 11 years	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5	3/29/2022-		
0094A	mL dosage, booster dose	8/31/2022	\$36.98*	N/A
Modern	a COVID-19 Bivalent Vaccine Booster Ages 6 to 11			
	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative			
91314	free, 25 mcg/0.25 mL dosage, for intramuscular use	10/12/22	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNLNP, spike protein, bivalent, preservative free, 25			
0144A	mcg/0.25 mL dosage, booster dose	10/12/22	\$36.98*	\$39.11*
Modern	a COVID-19 Vaccine Ages 12 and Up			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (Coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100	12/18/2020-		
91301	mcg/0.5mL dosage, for intramuscular use	04/18/23	\$0**	\$0**

	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100	12/18/2020-		
0011A	mcg/0.5mL dosage; first dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1			
	(ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage;	12/18/2020-		
0012A	second dose	04/18/23	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100	8/12/2021-		
0013A	mcg/0.5 mL dosage; third dose	04/18/23	\$36.98*	\$39.11*
Modern	a COVID-19 Vaccine Booster ages 18 and up			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50	10/21/2021-		
91306	mcg/0.25 mL dosage, for intramuscular use	8/31/2022	\$0**	N/A
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50	10/20/2021-		
0064A	mcg/0.25 mL dosage, booster dose	8/31/2022	\$36.98*	N/A
Modern	a Bivalent COVID-19 Vaccine Booster ages 18 and up			
	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative			
91313	free, 50 mcg/0.5 mL dosage, for intramuscular use	8/31/2022	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative free, 50			
0134A	mcg/0.5 mL dosage, booster dose	8/31/2022	\$36.98*	\$39.11*
Modern	a COVID-19 Vaccine Booster ages 18 and up & Primary Series Ages 6 to 11			

	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50	3/29/2022-		
91309	mcg/0.5 mL dosage, for intramuscular use	8/31/2022+	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5	3/29/2022-		
0094A	mL dosage, booster dose	8/31/2022	\$36.98*	N/A
Johnson	1 & Johnson (Janssen) COVID-19 Vaccine Administration Ages 18 and Up			
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus			
	disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26)	2/27/2021-		
	vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular	4/12/2021 &		
91303	use	4/23/2021	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease	2/27/2021-		
	[COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector,	4/12/2021 &		
0031A	preservative free, 5x1010 viral particles/0.5mL dosage, single dose	4/23/2021	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector,			
0034A	preservative free, 5x1010 viral particles/0.5 mL dosage; booster dose	10/20/2021	\$36.98*	\$39.11*
Novava	x COVID-19 Vaccine Administration Ages 18 and Up			
	Severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus			
	disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-			
91304	based	7/13/2022	\$0**	\$0**
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based			
0041A	adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose	7/13/2022	\$36.98*	\$39.11*

Office of MaineCare Services COVID-19 Vaccine Coverage Update April 18, 2023

	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease			
	[COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based			
0042A	adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose	7/13/2022	\$36.98*	\$39.11*
	Immunization administration by intramuscular injection of severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease			
	[COVID-19]) vaccine, recombinant spike protein nanoparticle, saponinbased			
0044A	adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose	10/19/22	\$36.98*	\$39.11*

^{*}MaineCare Usual, Customary, and Reasonable (UCR) Fee Schedule Rate. Section 45: Hospital Services claims shall be Ambulatory Payment Classification (APC) priced in accordance with CMS status.

⁺End Date effective for ages 18+ Booster dose only.

OMS	OMS Immunization Counseling Code Coverage			anuary 12, 2023
Code	Description	Code Effective Dates	Rate Effective 01/01/2022	Rate Effective 01/01/2023
EPDST	COVID-19 Immunization Counseling			
G0314	Immunization counseling by a physician or other qualified health care professional for COVID-19, ages under 21, 16-30 mins time. (This code is used for the Medicaid Early and Periodic Screening, Diagnostic, and Treatment Benefit (EPSDT).	06/08/22	\$35.46	\$35.46
G0315	Immunization counseling by a physician or other qualified health care professional for COVID-19, ages under 21, 5-15 mins time. (This code is used for the Medicaid Early and Periodic Screening, Diagnostic, and Treatment Benefit (EPSDT).	06/08/22	\$35.46	\$35.46
Stand A	alone Vaccine Counseling			
G0310	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time. (This code is used for Medicaid billing purposes.)	06/08/22- 06/30/22	\$6.15	N/A

^{**}Government supplied at no cost and billed with the SL modifier.

Immunization counseling by a physician or other qualified health care			
professional when the vaccine(s) is not administered on the same date of service,			
5 to 15 mins time. (This code is used for Medicaid billing purposes.)	07/01/22	\$26.63	\$26.63
Immunization counseling by a physician or other qualified health care			
professional when the vaccine(s) is not administered on the same date of service,	06/08/22-		
16-30 mins time. (This code is used for Medicaid billing purposes.)	06/30/22	\$6.15	N/A
Immunization counseling by a physician or other qualified health care			
professional when the vaccine(s) is not administered on the same date of service,			
16-30 mins time. (This code is used for Medicaid billing purposes.)	07/01/22	\$26.63	\$26.63
Immunization counseling by a physician or other qualified health care			
professional when the vaccine(s) is not administered on the same date of service			
for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing	06/08/22-		
purposes.)	06/30/22	\$6.15	N/A
Immunization counseling by a physician or other qualified health care			
professional when the vaccine(s) is not administered on the same date of service			
for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing			
purposes.)	07/01/22	\$26.63	\$26.63
Immunization counseling by a physician or other qualified health care			
professional when the vaccine(s) is not administered on the same date of service			
for ages under 21, 16-30 mins time. (This code is used for Medicaid billing	06/08/22-		
purposes.)	06/30/22	\$6.15	N/A
professional when the vaccine(s) is not administered on the same date of service			
for ages under 21, 16-30 mins time. (This code is used for Medicaid billing			
purposes.)	07/01/22	\$26.63	\$26.63
	professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing purposes.)	professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing 06/08/22-purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing 06/08/22-purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing 06/08/22-purposes.)	professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing purposes.) Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing purposes.)

^{*}MaineCare Usual, Customary, and Reasonable (UCR) Fee Schedule Rate. Section 45: Hospital Services claims shall be Ambulatory Payment Classification (APC) priced in accordance with CMS status.